- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04447898
Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Study Assessing the Safety and Immune Response of PPV-06 Vaccine in Patient With Inflammatory Knee Osteoarthritis (KOA)
PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is implicated in many inflammatory and autoimmune diseases such as rheumatoid arthritis and osteoarthritis. The benefit of vaccination with PPV-06 is to induce, in response to immunizations, the production of antibodies directed against IL-6. The antibodies produced will neutralize the biological activity of IL-6 involved in the body's inflammatory process.
The primary objective is to evaluate the safety/tolerability of vaccination with PPV-06.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Paris, France
- Recruiting
- CIC Cochin
-
Contact:
- François Rannou, MD
- Phone Number: 0033 1 58 41 25 48
- Email: francois.rannou@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged over 40 years;
- Diagnosis of primary inflammatory Knee Osteoarthritis (KOA),
- Body mass index (BMI) of 18-32 kg/m2 at screening;
- Patients with normal organ function at baseline
- Contraceptives measures
- In the investigator's opinion, the patient is capable and willing to comply with the requirements of the study;
- Willing and able to sign a written informed consent;
- Affiliated to social security insurance.
Exclusion Criteria:
- Systemic Autoimmune or immunodeficiency disease;
- Administration of non-steroidal anti-inflammatory drug (NSAID):
- Administration of prednisone or having intra-articular corticosteroid injection or bolus intramuscular or intravenous treatment with corticosteroids;
- Patients treated with biologics such as anti-TNFAlpha, anti-IL-6 and anti-CD-20
- Participation in another investigational drug or vaccine trial;
- Knee surgery planned before screening and throughout the study;
- Knee surgery within the year of baseline;
- Knee trauma within 2 months of baseline;
- Chronic hepatitis B and/or C infection. Patients with previous infection, resolved in the past, are eligible;
- HIV-positivity;
- History of allergic reaction to any constituents of the study drug;
- Diagnosis or history of any inflammatory arthritis;
- Neurologic disorders involving the lower limbs;
- History of malignancy within the last 5 years;
- Uncontrolled congestive heart failure or hypertension, unstable heart disease
- Evidence of any clinically significant abnormality on a chest X-ray which, in the opinion of the investigator, could represent active infection or latent tuberculosis;
- Moderate or severe acute illness/infection, persistent diarrhea or vomiting on the day of vaccination;
- Received any licensed, non-live vaccine within the 14 days before receipt of any dose of the study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of any dose of the study vaccine;
- Receipt of immune globulins, blood or blood-derived products;
- Pregnant or lactating females;
- The investigator considers the patient unfit for the study as a result of the medical interview, physical examination, or screening investigations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose
10 μg + Montanide™ ISA 51 VG
|
Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
|
Experimental: High dose
50 μg + Montanide™ ISA 51 VG
|
Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients with DLT defined as grade 3 or higher treatment-related adverse events (monitored in all patients during the study treatment until the End of Study (Week 42) or early termination).
Time Frame: From Baseline to Week 42 (End of Study)
|
The primary outcome measure of this study is to evaluate the safety/tolerability of PPV-06 vaccination
|
From Baseline to Week 42 (End of Study)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The occurrence of all adverse events (AEs) and serious adverse events (SAEs), including clinically significant abnormal haematological and biochemical values (monitored during the entire study period until End of Study (Week 42) or early termination).
Time Frame: From Baseline to Week 42 (End of Study)
|
This secondary outcome measure of this study is to evaluate additional indicators of safety / tolerability
|
From Baseline to Week 42 (End of Study)
|
The quantification of inflammatory markers will be assessed at Baseline, W4, W12, W16, W24, W32 and End of Study (Week 42) or early termination by measuring IL-6, hsCRP and CRPM level in blood
Time Frame: From Baseline to Week 42 (End of Study)
|
This secondary outcome measure of this study is to evaluate additional indicators of safety / tolerability
|
From Baseline to Week 42 (End of Study)
|
The quantification of Anti-IL-6 antibody production, isotypes characterization and anti-CRM197 antibody level in serum at Baseline, W4, W12, W16, W24, W32 and EoS or early termination
Time Frame: From Baseline to Week 42 (End of Study)
|
This secondary outcome measure of this study is to evaluate the humoral immune response of PPV-06
|
From Baseline to Week 42 (End of Study)
|
The quantification of Anti-IL-6 neutralizing antibody level in vitro at W4, W12, W16, W24, W32 and EoS or early termination
Time Frame: From Baseline to Week 42 (End of Study)
|
This secondary outcome measure of this study is to evaluate the humoral immune response of PPV-06
|
From Baseline to Week 42 (End of Study)
|
The quantification of specific T cell response and polarization (Th1, Th2 and Th17) assessed by IFNg, IL-5 and IL-17 Elispot assay at Baseline, W24, W32 or early termination.
Time Frame: From Baseline to Week 42 (End of Study)
|
This secondary outcome measure of this study is to evaluate the cellular immune response of PPV-06
|
From Baseline to Week 42 (End of Study)
|
The quantification of proliferative CD4+T cells assessed by flow cytometry at Baseline, W24, W32 or early termination.
Time Frame: From Baseline to Week 42 (End of Study)
|
This secondary outcome measure of this study is to evaluate the cellular immune response of PPV-06
|
From Baseline to Week 42 (End of Study)
|
The frequency of hIL-6 epitope-specific memory B cells assessed by ELISPOT assay, at Baseline, W24, W32 or early termination.
Time Frame: From Baseline to Week 42 (End of Study)
|
This secondary outcome measure of this study is to evaluate the cellular immune response of PPV-06
|
From Baseline to Week 42 (End of Study)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PPV06-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on PPV-06 10 μg
-
CytoAgents, Inc.TFS HealthScienceRecruitingCytokine Release SyndromeUnited States
-
Percutaneous Systems, Inc.Terminated
-
AllerganTerminatedGastroparesisUnited States, Spain, Italy, Australia, Russian Federation, Canada, India, Thailand, France, Malaysia, Denmark, Korea, Republic of, Bulgaria, Germany, Poland, Singapore, Mexico, Israel, Philippines, Ukraine, Belgium, South Africa, A... and more
-
WestatEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPNC Vaccine | HIV-infected Pregnant WomenBrazil
-
Chang Gung Memorial HospitalNational Science Council, TaiwanCompleted
-
Trinomab Biotech Co., Ltd.TIGERMED AUSTRALIA PTY LIMITEDCompletedHealthy Adult SubjectsAustralia
-
Baylor College of MedicineGeorge Washington University; Children's National Research InstituteCompletedHookworm Infection | Hookworm DiseaseUnited States
-
VA Office of Research and DevelopmentNational Cancer Institute (NCI); Jonsson Comprehensive Cancer CenterTerminatedNon-Small Cell Lung Cancer (NSCLC)United States
-
Leiden University Medical CenterGöteborg University; Walter Reed Army Institute of Research (WRAIR); PATH; European... and other collaboratorsNot yet recruitingShigellosis | Bacillary DysenteryNetherlands
-
PfizerJANSSEN Alzheimer Immunotherapy Research & Development, LLCCompletedAlzheimer's DiseaseUnited States